… Measurement of tumor perfusion using positron emission … (NSCLC) using H 2 15 O and
positron emission tomography. … performed in 10 patients with stage IIIA-N2 NSCLC. Blood flow (…

… stage IIIA-N2 NSCLC patients with surgical treatment at our institution who fulfilled the
inclusion criteria were entered in this prospective study with informed consent. Stage IIIA-N2 was …

… Induction therapy is often recommended for patients with clinical stage IIIA-N2 (cIIIA/pN2)
lung cancer. We examined whether postinduction positron emission tomography (PET) scans …

… IIIA-N2 non-small cell lung cancer (NSCLC) is at present studied extensively. To select
patients with truly stage IIIA-N2 … -d-glucose positron emission tomography (FDG PET) in IIIA-N2 …

Purpose Surgical resection in patients with stage IIIA-N2 non–small-cell lung cancer (NSCLC)
is usually reserved for patients with mediastinal downstaging after induction …

… tumors and N2 nodes on positron emission tomography (PET) in patients with stage IIIA N2
non… and proved pathologically to have stage IIIA N2 disease between January 2000 and April …

… Pathologically, N2 disease has been referred to as bulky, … N2 disease in only 2.9% and
3.7%, respectively, of patients with NSCLC who are staged as N0 after both positron emission …

… tion of "N labeled nitrogen gas in a normal volunteer. The concentration was approximately
… Following the equilibrium scan, the radioactive nitrogen gas was washed out with room air …

… Positron-emission tomography correctly differentiated resectable stages IA … IIIA (N1)
from stages IIIA (N2) through IV in 88.7% of cases. In identifying N2 or N3 disease, positron-emission …

… A prospective trial of patients with biopsy-proven N2 disease who underwent initial
clinical staging with mediastinoscopy, integrated positron emission tomography/computed …